Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Stem Cell Mobilization in Lymphoma and Multiple Myeloma
NCT06026995Phase 4Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in lymphoma and multiple myeloma (MM) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Proportion of patients with CD34+ cells >= 2x10^6/kg at 28 days. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06026995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026995.